Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:8997
Name polycythemia vera
Definition A myeloproliferative neoplasm characterized by erythroid hyperplasia, myeloid leukocytosis, thrombocytosis, and splenomegaly.
Source DiseaseOntology.org
Alt Ids DOID:11868
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm myeloproliferative neoplasm polycythemia vera


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
JAK2 V617F Ropeginterferon polycythemia vera sensitive detail...
IDH1 mutant N/A polycythemia vera not applicable detail...
IDH2 mutant N/A polycythemia vera not applicable detail...
JAK2 V617F INCB053914 polycythemia vera predicted - sensitive detail...
JAK2 V617F N/A polycythemia vera not applicable detail...
JAK2 exon12 N/A polycythemia vera not applicable detail...
JAK2 V617F C220 polycythemia vera predicted - sensitive detail...
JAK2 V617F C220 + Ruxolitinib polycythemia vera predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02038036 Phase III Peginterferon alfa-2b Anagrelide Hydroxyurea Pipobroman Ruxolitinib Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (RESPONSE-2) Completed ITA | FRA | ESP | DEU | CAN | BEL 6
NCT02493530 Phase I Ruxolitinib + Umbralisib TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea Active, not recruiting USA 0
NCT03287245 Phase II Idasanutlin A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera Terminated USA | ITA | CAN 1
NCT03669965 Phase II Ruxolitinib KRT-232 KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera Active, not recruiting USA | FRA | ESP | DEU 2
NCT03862157 Phase Ib/II Azacitidine + MLN4924 + Venetoclax Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04041050 Phase I Navitoclax Navitoclax + Ruxolitinib A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm Recruiting USA | ITA | FRA | ESP | DEU | BEL 9
NCT04116502 Phase III Ruxolitinib Hydroxyurea Alpha 2 Interferon MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera (MITHRIDATE) Recruiting 1
NCT04262141 Phase II IMG-7289 IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Recruiting USA 0
NCT04282187 Phase II Decitabine + Fedratinib Decitabine + Ruxolitinib Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms Recruiting USA 0
NCT04644211 Phase II Ruxolitinib Ruxolitinib in Thrombocythemia and Polycythemia Vera Not yet recruiting USA 0
NCT04955938 Phase I Enasidenib + Fedratinib Fedratinib + Ivosidenib A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Recruiting USA 0
NCT05127174 Phase Ib/II Fedratinib Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms Recruiting USA 0